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As the search for molecular therapies for basal ganglia
disorders, such as Parkinson’s disease, accelerates,
new neurobiological information is also leading to
renewed interest in neurosurgical approaches.
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The motor symptoms of basal ganglia disorders fall at two
extremes. In Parkinson’s disease and related parkinsonian
states, patients have difficulty in initiating movements. In
Huntington’s disease and related choreoathetotic disor-
ders, patients make unwanted movements. Evidence has
long placed two brain structures at the center of research
on these disorders: the dopamine-synthesizing substantia
nigra of the midbrain, which degenerates in Parkinson’s
disease, and the striatum of the forebrain, which degener-
ates in Huntington’s disease. How neurodegeneration in
these two nuclei could bring about such different symp-
toms has so far not made much neurobiological sense. The
dopamine-containing cells of the substantia nigra innervate
the striatum, so it appears that loss of dopaminergic inner-
vation of the striatum produces the hypokinetic disorder of
Parkinson’s disease; and yet the loss of striatal cells them-
selves produces hyperkinetic disorders such as Hunting-
ton’s disease. New neurobiological clues to the functional
organization of the basal ganglia are now helping with both
molecular biological and more classical approaches to
treating these debilitating neurological disorders.
The potential of the molecular approach is demonstrated
by the recent cloning of the Huntington’s disease gene
[1] and identification of proteins that interact with the
gene’s product, Huntingtin [2]. These represent major
steps towards the development of a gene-based therapy
for Huntington’s disease. But what about Parkinson’s
disease, which is not associated with a clear genetic
defect? The success of L-DOPA in relieving symptoms of
Parkinson’s disease was a pioneering example of a
successful molecular-replacement therapy in neurology;
L-DOPA is the biosynthetic precursor of dopamine.
L-DOPA-based therapies tend, however, to lose effec-
tiveness with time, and L-DOPA itself can induce abnor-
mal and debilitating motor side effects (dyskinesias).
Even without a clear genetic basis for Parkinson’s disease,
new molecular approaches to manipulating the dopamine
system are being developed.
By targeted gene inactivation, ‘knockout’ mice have been
generated that lack single dopamine receptor subtypes
[3–7], or the dopamine transporter [8]. The receptor
mutants demonstrate clear receptor-specific effects of
dopamine on neurotransmission and behavior, and the
transport mutants show remarkable behavioral changes as
well. These mutant mice will be of great value in speed-
ing the development of new pharmacological treatment of
dopamine-based disorders. They also bring surprises
about the molecular events responsible for the effects of
addictive drugs such as amphetamine and cocaine. 
Zhou and Palmiter [9] have used an imaginative combined
knockout/transgene strategy to generate mutant mice that
specifically lack dopamine in the substantia nigra. They
first generated knockout mice lacking tyrosine hydroxy-
lase, an enzyme involved in synthesis of catecholamines
such as dopamine and noradrenaline. The knockout mice
die as embryos, but could be rescued by a tyrosine hydrox-
ylase transgene that conferred synthesis of noradrenaline,
but not dopamine, in neurons of the noradrenergic locus
coeruleus. The rescued mice showed the classical signs of
dopamine deficiency, dying at about two weeks of age. If
given L-DOPA therapy, however, the mice lived and
showed great improvement on all but the most complex
motor tasks. Even more selective targeting strategies,
using cell- or region-specific promoter sequences, offer
great potential for devising new gene-based therapies.
A development in molecular biology that has clear thera-
peutic potential for treating Parkinson’s disease is the
cloning of genes encoding neurotrophins and growth
factors. For example, glial-derived neurotrophic factor
(GDNF) has been reported to halt the progression of
degeneration in the substantia nigra induced by the
neurotoxin MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydro-
pyridine) [10] or by axotomy [11], and preliminary tests of
GDNF infusion to reduce symptoms in primate parkinson-
ian models are reported as being promising [12]. Even the
signalling molecule Sonic hedgehog, known to have impor-
tant roles in a number developmental contexts, may be an
important player — it can induce neurons of the developing
midbrain to differentiate with a dopaminergic phenotype in
vitro [13]. These results suggest new therapeutic strategies
in which molecules that promote the differentiation or sur-
vival of dopaminergic neurons are delivered to appropriate
targets by using infusion techniques or transplantation.
At a time when molecular genetic techniques are advanc-
ing so rapidly and seem so promising, it is ironic that
neurosurgery, a traditional and often last-hope approach to
basal ganglia disorders, is re-emerging as a major way of
treating Parkinson’s disease [14–22]. The renewed inter-
est in neurosurgical treatments for Parkinson’s disease is
based on the use of new neurobiological information to
determine precise targets for the brain lesions. The central
idea prompting the neurosurgical effort is that the
extremes of motor disability found in hypokinetic and
hyperkinetic basal ganglia disorders reflect imbalances
between two major basal ganglia pathways: a ‘direct’
pathway (or family of pathways) from the striatum to
motor executive regions, and an ‘indirect’ pathway that
modulates the direct one (Fig. 1) [23–25]. 
Both the direct and the indirect pathways lead to parts of
the globus pallidus and to the non-dopaminergic (reticular)
part of the substantia nigra. The direct pathway leads on to
the thalamus and frontal cortex or, via the substantia nigra,
to the brainstem. The neocortex can excite this direct
pathway by releasing an excitatory amino acid, such as
glutamate, from corticostriatal terminals, and because two
inhibitory — g-amino-butyric acid (GABA)-releasing —
synapses then follow in a row (Fig. 1), the circuit is
thought to activate cortical and brainstem movement
centers. The indirect pathway is supposed to have exactly
the opposite effect, because it includes an excitatory link
in a small but pivotal nucleus, the subthalamic nucleus.
The subthalamic nucleus turns on inhibition in the direct
pathway. This push-pull system, so current notions go,
works by enhancing movement through activity in the
direct path and diminishing it through activity in the indi-
rect path ([23,24], but see [26]). This notion has shifted
the therapeutic focus away from the dopaminergic sub-
stantia nigra and striatum to the pallidum and subthalamic
nucleus. 
Neurosurgical lesions are being made — first in MPTP-
treated parkinsonian monkeys [27] and now in patients
with Parkinson’s disease [14,16–18,21,22] — to increase
mobility by decreasing tonic direct pathway inhibition of
the thalamus. Localized high-frequency stimulation deliv-
ered by portable stimulators is also being vigorously
pursued as a way of making reversible, ‘functional lesions’
[15,19,20]. The targets for the lesions are the subthalamic
nucleus, the thalamus and now (the preference of many
groups) the internal segment of the globus pallidus (Fig.
1). Dramatic and immediate symptomatic relief can occur
with a posteroventral pallidal lesion, as originally docu-
mented by Leksell [14] and Laitinen [16] and their
coworkers. Most patients remain on L-DOPA, however,
and reports based on careful ongoing studies (for example
[22]) do not make claims of complete reversal of symp-
toms. Long-term follow-ups have not yet been possible. 
A key feature of the pallidotomy procedure appears to be
to confine the lesion to the most strictly ‘motor’ (pos-
teroventral) part of the pallidum and/or associated fiber
bundles. This requires demanding collaborative efforts of
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Figure 1
Summary of basal ganglia circuits. Five key
nuclei of the circuit are shown in pale green.
Major inputs to the circuit lead to the striatum
from the cerebral cortex, the amygdala and
the intralaminar thalamus (CM-Pf). The
striatum (which degenerates in Huntington’s
disease) is the source of three key pathways
through the basal ganglia: First, the direct
pathway (blue), which has two GABAergic
inhibitory links in a row, so that activation of
the striatum is thought to disinhibit (‘release’)
the motor thalamus and subsequently the
frontal cortex, as well as midbrain structures
such as the superior colliculus and
pedunculopontine nucleus (PPN). Second,
the indirect pathway (red), which is thought to
work in opposition to the direct pathway
because of the added link through the
subthalamic nucleus (Sth N) which excites
direct pathway inhibitory function. And third,
the striatonigral pathway to the pars
compacta of the substantia nigra (SNc),
which forms a loop (yellow) with the
dopamine-containing nigrostriatal pathway
that degenerates in Parkinson’s disease. The
two segments of the pallidum are also
interconnected (purple). For clarity, a number
of subcircuits have been omitted. Grey arrows
point to sites of neurosurgical intervention by
lesions or stimulation in  Parkinson’s disease
patients; the arrow pointing to the globus
pallidus (GPi) indicates the site of
posteroventral pallidotomy discussed in text.
Most growth factor/neurotrophin and
transplant strategies are directed toward the
nigrostriatal system. SNr, non-dopaminergic
(reticular) part of the substantia nigra.
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neurosurgeons, neurologists and physiologists to identify
the critical target site with extracellular recording
methods.
Following posteroventral pallidotomy, a striking normal-
ization of metabolic activity in the premotor/supplemen-
tary motor cortex has been demonstrated by positron
emission tomography (PET) scans [18,28]. This finding
strongly supports the notion that the pallidal lesion
decreases inhibition of thalamo-cortical circuits. Ironi-
cally, however, one of the great successes of the pos-
teroventral pallidotomy procedure calls into question
some of the notions on which the surgery is based.
Opinion is growing that the procedure is strikingly effec-
tive in reducing L-DOPA-induced dyskinesias (for
example [21,22]), and it is not at all clear how this could
fit with enabling movement in Parkinson’s patients.
Another puzzle is how the symptomatic relief can be so
great when the treatment does not, apparently, involve
the reticular part of the substantia nigra, which contains
many direct path neurons affecting movement (Fig. 1).
Finally, there are questions about whether the pallidal
lesions have cognitive effects as well — and, if so, what
mechanisms might underlie such effects.
Molecular therapies based on this notion of direct and
indirect pathways are also rapidly being developed. Gluta-
mate receptors are reasonable targets for such efforts to
control interactions between the direct and indirect path-
ways [29], as are receptors for peptides coexpressed with
GABA in the direct and indirect pathways [25,30]. Interest
is also shifting back to the nigrostriatal system, especially
as studies of knockout mice clearly show that dopamine
D1 and D2 receptors can selectively control the expression
of direct and indirect pathway neuropeptides. D1 receptor
mutants have sharply diminished basal ganglia expression
of dynorphin [3] and substance P [3,4], the neuropeptides
coexpressed with GABA in the direct pathway, whereas
D2 receptor mutants show loss of basal ganglia expression
of enkephalin, the neuropeptide coexpressed with GABA
in the indirect pathway [7]. These contrasting effects
suggest that dopamine, acting at D1 and D2 receptors, can
selectively affect the functioning of the direct and indirect
pathways.
Perhaps the most optimistic view to take is that, while
gene- and growth-factor-based therapies are being
devised to prevent neurodegeneration, strategies aimed at
symptomatic relief of Parkinson’s disease and other basal
ganglia disorders can profit from innovative combinations
of molecular biology and neurosurgery. There is, more-
over, a real possibility that, as more is learned about the
neurobiology of the basal ganglia, these strategies can be
applied to conditions involving, not only the motor symp-
toms of basal ganglia dysfunction, but the cognitive and
affective symptoms as well.
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